Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

732
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
732
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

685
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
685
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

414
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
414
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Blood·2026
Same author

Splenic FDG PET uptake and CT volume as prognostic biomarkers in diffuse large B cell lymphoma.

La Radiologia medica·2026
Same author

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study.

Blood advances·2026
Same author

Describing the use of ruxolitinib for the treatment of myelofibrosis: a plain language summary of the ROMEI early study results.

Future oncology (London, England)·2026
Same author

Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients.

Leukemia & lymphoma·2026

Related Experiment Video

Updated: Apr 17, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.9K

Everolimus in diffuse large B-cell lymphomas.

Michele Merli1, Andrea Ferrario, Margherita Maffioli

  • 1Division of Hematology, University Hospital Ospedale di Circolo & Fondazione Macchi, Viale L Borri 57, 21100 Varese, Italy.

Future Oncology (London, England)
|February 13, 2015
PubMed
Summary
This summary is machine-generated.

Everolimus shows promise for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This mTOR inhibitor demonstrated significant activity and good tolerability, both alone and in combination with rituximab.

Keywords:
diffuse large B-cell lymphomaeverolimusmTOR pathwayrapamycin analogs

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K

Related Experiment Videos

Last Updated: Apr 17, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.9K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) presents challenges in relapsed/refractory settings.
  • The mechanistic target of rapamycin (mTOR) pathway is frequently dysregulated in DLBCL.
  • Novel therapeutic strategies targeting the mTOR pathway are needed for DLBCL treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of everolimus, an oral mTOR inhibitor, in patients with relapsed/refractory DLBCL.
  • To assess the combination of everolimus with rituximab in this patient population.

Main Methods:

  • A large Phase II study investigated everolimus at a 10 mg daily dose in relapsed/refractory DLBCL.
  • Preclinical studies informed the selection of everolimus and its dosing.
  • Combination therapy with rituximab was also evaluated.

Main Results:

  • Everolimus monotherapy achieved a 30% overall response rate in relapsed/refractory DLBCL.
  • The primary toxicity observed with everolimus was thrombocytopenia.
  • The combination of everolimus and rituximab demonstrated an objective response rate of 38% with a 13% complete response rate, without increased toxicity.

Conclusions:

  • Everolimus exhibits substantial activity and good tolerability in relapsed/refractory DLBCL.
  • The combination of everolimus and rituximab shows encouraging efficacy in DLBCL.
  • Further investigations of everolimus in combination therapies for DLBCL are warranted.